MHRA paediatric investigation plan
LysoPhosphatidic Acid receptor 1 (LPA1) antagonist (BMS-986278) (LysoPhosphatidic Acid receptor 1 (LPA1) antagonist (BMS-986278))
MHRA paediatric investigation plan MHRA-100995-PIP01-23 · Waiver
Key facts
| PIP number | MHRA-100995-PIP01-23 |
|---|---|
| Active substances | LysoPhosphatidic Acid receptor 1 (LPA1) antagonist (BMS-986278) |
| Therapeutic areas | Pneumology - Allergology |
| Conditions | Treatment of fibrosing Interstitial Lung Diseases (ILD) |
| Decision | W: decision granting a waiver in all age groups for the listed condition(s). |
| Published | Dec 19, 2023 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: